Innovative Pharmacogenomics OneOme specializes in personalized medicine through evidence-based pharmacogenomic solutions, making it a key partner for healthcare providers seeking to enhance medication management and patient outcomes with cutting-edge genetic insights.

Strong Industry Recognition Recognized as one of Fast Company’s 50 Most Innovative Companies of 2018, OneOme’s reputation for innovation can be leveraged to build trust and open doors with healthcare organizations focused on technological advancements.

Strategic Partnerships Collaborations with entities like Tabula Rasa Healthcare and Azova demonstrate a network of integrated healthcare solutions, offering potential for joint sales strategies and expanding the reach of pharmacogenomics testing services.

Expanding Genetic Capabilities Recent updates to the RightMed test, including additional genes and medications, indicate ongoing product innovation which can appeal to hospitals and clinics looking for comprehensive, up-to-date genetic testing options.

Market Growth Potential With revenues between 10 to 25 million and a focus on cost-effective, personalized solutions, OneOme presents opportunities to engage healthcare providers, payers, and labs investing in precision medicine to improve care and reduce treatment costs.